Cellectis S.A (CLLS) Fair Value & Analysis
Healthcare · US · Market cap $317M
Cellectis S.A
CLLS · US
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 6 days ago
Share price −14.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.47 – $5.17 · fair‑value band $3.53 – $5.88 · the $2.90 price screens below the $4.70 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Cellectis S.A (CLLS) currently trades at $2.90, while our model-based Fair Value estimate is $4.70 — implying the stock looks roughly 62.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Cellectis S.A generated revenue of $75.1M at a net margin of -89.5%. Revenue declined 37.3% year over year. It earns a return on equity of -76.3%. Net debt stands at $56.3M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cellectis S.A reported revenue of $72.9M in FY2025 versus $73.9M in FY2021, a compound −0.3%/yr. Reported net income was −$67.6M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cellectis S.A (CLLS) undervalued?
What is the fair value of CLLS?
What is the quality score of CLLS?
What is the revenue of Cellectis S.A (CLLS)?
What is the net profit margin of CLLS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.